Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytotect CP for CMV prophylaxis in acute grade II–IV GVHD after allogeneic HCT
2020-004698-30Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Mar 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of human cytomegalovirus immune globulin in cytomegalovirus disease (CMV), sponsored by CHU de Lille. Primary endpoint: Rate of CMV infection within 16 weeks of Cytotect CP therapy. Started Mar 2021; status: completed.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2020-004698-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004698-30.